Yes we PanCAN

A major goal of a new multidrug platform study organized by the Pancreatic Cancer Action Network is to meet patients' needs better than traditional trials do. Among other things, that means accepting patients who have had a wide range of prior therapies and allowing them to cross over to new treatments following progression. It also means incorporating individual patient preferences into the randomization algorithms.

PanCAN believes Precision Promise will dramatically increase the proportion of pancreatic cancer patients who participate in clinical trials, which Chief Research Officer Lynn Matrisian told BioCentury has been a barrier to development of new treatments...